Independent Franchise Partners
US Equity Fund
Independent Franchise Partners Bristol-Myers Squibb Company stake
total: 60
US Equity Fund BMY trades
- Total transactions:
- 26
- New positions:
- 1
- Added:
- 12
- Reduced:
- 13
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Independent Franchise Partners holds 1,586,498 Bristol-Myers Squibb Company (BMY) shares with a market value of roughly $96.22M accounting for 6.51% of the overall portfolio. To date, the estimated cost basis is nearly $55.75 for "buy" trades and estimated average "sell" price is $61.46. US Equity Fund first purchased BMY in 2019 Q3, initially acquiring about 1.10M shares. Since the initial investment in Bristol-Myers Squibb Company (BMY), US Equity Fund has made 25 more transactions.
When did Independent Franchise Partners buy Bristol-Myers Squibb Company (BMY)?
Independent Franchise Partners first invested in Bristol-Myers Squibb Company (BMY) in 2019 Q3 at the reported quarter-end price of $50.71 per share.
What's the cost basis of US Equity Fund's BMY stake?
The estimated cost basis for Bristol-Myers Squibb Company (BMY) stake is around $55.75 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $55.75
- Weighted AVG sell price:
- $61.46
Independent Franchise Partners's historical trades in Bristol-Myers Squibb Company
26 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
6.51%
|
1,586,498
|
$60.65
|
$96,221,104
|
+2.43% (+37,624)
|
+0.15%
|
|
2025 Q4
|
5.33%
|
1,548,874
|
$53.94
|
$83,546,264
|
-8.53% (-144,413)
|
-0.48%
|
|
2025 Q3
|
4.66%
|
1,693,287
|
$45.10
|
$76,367,244
|
+5.22% (+84,025)
|
+0.23%
|
|
2025 Q2
|
5.13%
|
1,609,262
|
$46.29
|
$74,492,738
|
+39.29% (+453,930)
|
+1.45%
|
|
2025 Q1
|
5.05%
|
1,155,332
|
$60.99
|
$70,463,699
|
+24.28% (+225,722)
|
+0.99%
|
|
2024 Q4
|
4.78%
|
929,610
|
$56.56
|
$52,578,742
|
-45.69% (-782,074)
|
-2.26%
|
|
2024 Q3
|
4.52%
|
1,711,684
|
$51.74
|
$88,562,530
|
-4.26% (-76,215)
|
-0.21%
|
|
2024 Q2
|
3.95%
|
1,787,899
|
$41.53
|
$74,251,445
|
-4.31% (-80,598)
|
-0.17%
|
|
2024 Q1
|
5.20%
|
1,868,497
|
$54.23
|
$101,328,592
|
+7.60% (+132,049)
|
+0.37%
|
|
2023 Q4
|
4.81%
|
1,736,448
|
$51.31
|
$89,097,147
|
-0.96% (-16,838)
|
-0.05%
|
|
2023 Q3
|
5.78%
|
$58.04
|
+9.81% (+156,618)
|
|||
|
2023 Q2
|
5.47%
|
$63.95
|
+18.21% (+246,011)
|
|||
|
2023 Q1
|
5.55%
|
$69.31
|
-0.20% (-2,751)
|
|||
|
2022 Q4
|
6.23%
|
$71.95
|
-3.04% (-42,475)
|
|||
|
2022 Q2
|
6.77%
|
$77.00
|
-16.13% (-268,538)
|
|||
|
2022 Q1
|
6.49%
|
$73.03
|
-10.66% (-198,499)
|
|||
|
2021 Q4
|
5.58%
|
$62.35
|
+24.59% (+367,689)
|
|||
|
2021 Q3
|
4.42%
|
$59.17
|
-1.90% (-28,972)
|
|||
|
2021 Q2
|
5.04%
|
$66.82
|
+18.74% (+240,542)
|
|||
|
2021 Q1
|
4.21%
|
$63.13
|
+20.66% (+219,765)
|
|||
|
2020 Q4
|
3.58%
|
$62.03
|
-0.61% (-6,525)
|
|||
|
2020 Q3
|
3.93%
|
$60.29
|
-12.47% (-152,465)
|
|||
|
2020 Q2
|
4.54%
|
$58.80
|
+14.62% (+156,025)
|
|||
|
2020 Q1
|
4.47%
|
$55.74
|
+28.51% (+236,688)
|
|||
|
2019 Q4
|
3.36%
|
$64.19
|
-24.46% (-268,842)
|
|||
|
2019 Q3
|
2.75%
|
$50.71
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.